Nortriptyline for Treatment-Resistant Depression
J Clin Psychiatry 2003;64(1):35-39
© Copyright 2017 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Background: Up to 30% of patients with
major depression fail to respond to an antidepressant trial, with
most taking a selective serotonin reuptake inhibitor (SSRI) as
initial treatment. While the tricyclic antidepressants might be
effective for SSRI nonresponders, they have been relegated to
third- and fourth-line treatment. This study assesses the
efficacy of nortriptyline for patients with treatment-resistant
Method: 92 patients with
treatment-resistant DSM-III-R major depression, with resistance
defined by at least 1, but no more than 5, well-documented
adequate trials of antidepressants during the current episode,
were treated openly with nortriptyline for 6 weeks. Patients were
titrated up to full target doses of nortriptyline within 1 week,
with target blood levels of 100 ng/mL. Response was defined as a
50% or greater decrease of baseline 17-item Hamilton Rating Scale
for Depression score. We performed an intent-to-treat analysis
with the last observation carried forward.
Results: Approximately 40% of patients
were responders (N=39) and 12% were remitters (N=11) after 6
weeks of nortriptyline. Over a third of patients were unable to
complete the trial.
Conclusion: Nortriptyline was effective
for over a third of patients with treatment-resistant depression,
and nortriptyline should be considered as potential treatment if
patients fail to respond to other antidepressants.